Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results and Pipeline Progress
Summary
Ionis Pharmaceuticals, Inc. reported its financial results for the quarter and fiscal year ended December 31, 2025, revealing substantial revenue growth and exceeding its guidance. The company generated $944 million in total revenue for the year, with significant contributions from its commercialized products and R&D collaborations. Ionis also highlighted advancements in its pipeline, with several products poised for launches and regulatory submissions in 2026, including TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, and zilganersen for Alexander disease. The company's 2026 financial guidance anticipates continued growth, with a modest increase in operating expenses to support ongoing and upcoming launches.
Profitelligence Alerts
Get alerts for IONS
Be first to know when Ionis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Official SEC Documents
Advertisement